News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Joe Chang: Optimal first-line treatment for EGFR-mutated mNSCLC
Joe Y. Chang/X
Mar 30, 2025, 16:56

Joe Chang: Optimal first-line treatment for EGFR-mutated mNSCLC

Joe Chang, Director of the Stereotactic Ablative Radiotherapy Program at MD Anderson Cancer Center, shared a post on X:

“Optimal first-line treatment for EGFR-mutated mNSCLC?

  1. Tagrisso alone for most patients.
  2. Tagrisso plus chemo for high-risk patients (brain/liver mets or large size)
  3. Amivantamab: Ab EGFR and MET. Lazertinib: EGFR TK

Don’t forget: SABR plus Tagrisso for oligomets or oligoprogression.”

Joe Chang: Optimal first-line treatment for EGFR-mutated mNSCLC

More posts featuring Joe Chang.

cancer EGFR Joe Chang mNSCLC OncoDaily Oncology
Special Coverage
Insight
Jun 1, 2025, 14:56
Debra Patt on the Importance of Policy Engagement in Oncology at ASCO 2025
Insight
Jun 1, 2025, 14:52
Key Insights by Tom Powles from ASCO25
Insight
Jun 1, 2025, 14:50
Pashtoon Kasi Highlighted Study on Vilastobart (XTX101) + Atezolizumab in MSS Colorectal Cancer at ASCO 2025
Science
Jun 1, 2025, 14:48
First results of SURE-02 Trial presented at ASCO 2025 by Andrea Necchi
Insight
Jun 1, 2025, 14:41
Aakash Desai: Interim Results from Our Phase 1 Trial of PDL1V, a Vedotin-Based ADC Targeting PD-L1 in R/R NSCLC at ASCO 2025
Blog
Jun 1, 2025, 14:39
Christina Ip-Toma: Integrating germline and tumor genetic results to reduce disparities in cancer care
Blog
Jun 1, 2025, 14:38
Key Insights by Petros Grivas from ASCO25
Science
Jun 1, 2025, 14:38
Kriti Mittal: The ASCO special edition of the ASPIRE CoP newsletter
Oncolibrary
Jun 1, 2025, 13:48
Romiplostim for Chemotherapy-induced Thrombocytopenia Results from global phase iii trial in Gi cancers
Opinion
Jun 1, 2025, 13:42
Efficacy of IL-6R Blockade with Sarilumab in a Quadruple Immuno-Oncology Regimen for Patients with Unresectable Stage III/IV Melanoma
Oncolibrary
Jun 1, 2025, 13:02
CheckMate 214 Trial Final 9-Year Results at ASCO 2025: Nivolumab Plus Ipilimumab Continues to Show Long-Term Survival Benefit in Advanced Renal Cell Carcinoma
Oncolibrary
Jun 1, 2025, 12:40
Metacure Cohorts B2 Results: Intensified Hormonal Blockade and SBRT for PSMA-PET Detected Oligometastatic Prostate Adenocarcinoma